ALBHF:OTC-Alibaba Health Information Technology Limited (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 0.554

Change

0.00 (0.00)%

Market Cap

USD 8.27B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, health food, adult and family planning products, healthcare and skincare products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, appointment-booking, vaccination, dental care, mental care, optometry, and nursing services, as well as traditional Chinese medicines. The company provides is products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; provision of network hospital, software technical services, healthcare related internet information and technical services; operation of internet hospitals, as well as Doctor U, an intelligent and one-stop platform for doctor and patient education; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.16B
JDHIF JD Health International Inc

N/A

USD 9.97B
RADLY Raia Drogasil SA ADR

-0.29 (-5.87%)

USD 7.74B
CLCGY Clicks Group Ltd

+0.63 (+1.50%)

USD 5.11B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.23B
SAEYY Shop Apotheke Europe N.V

N/A

USD 3.16B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

-3.47 (-8.17%)

USD 0.54B
NVACF Nova Cannabis Inc

N/A

USD 0.08B
PNPL Pineapple Express

N/A

USD 0.01B

ETFs Containing ALBHF

CHIH 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.40% 53% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.40% 53% F 54% F
Trailing 12 Months  
Capital Gain -15.48% 53% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.48% 53% F 39% F
Trailing 5 Years  
Capital Gain -44.04% 79% B- 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.04% 79% B- 40% F
Average Annual (5 Year Horizon)  
Capital Gain -13.66% 28% F 17% F
Dividend Return -13.66% 28% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 60.47% 72% C 46% F
Risk Adjusted Return -22.59% 28% F 23% F
Market Capitalization 8.27B 90% A- 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.